Novartis to Acquire Avidity Biosciences for $12 Billion
Novartis has agreed to acquire Avidity Biosciences for approximately $12 billion in cash, with the deal expected to close in the first half of 2026 following the planned separation of Avidity’s early-stage cardiology programs into a new company called SpinCo.